Ohio Department of Medicaid (ODM) Drug Utilization Review (DUR) Board Quarterly Meeting

May 14, 2019

The ODM DUR Board meeting was called to order at 12:05 PM EST in room C621 A&B
50 West Town Street, Columbus, Ohio. A. Mehran Mostafavifar, M.D. presided.

The following Board members were present:
   Michelle Barger, Pharm.D.
   David Brookover, R.Ph.
   Michael Dietz, D.O., Co-Chair.
   Michael Farrell, M.D.
   A. Mehran Mostafavifar, M.D., Chair
   Lenard Presutti, D.O.
   Stacey Rexrode-Brewer, Pharm.D.

Also present from ODM were Tracey Archibald, Pharm.D., and Scott Baran, R.Ph. Change Healthcare attendees included Jill R.K. Griffith B.S. Pharm.D., Benjamin Link Pharm.D., and Gail Master, R.Ph. Approximately 21 observers were present, mostly representing pharmaceutical manufacturers.

Roll Call, Reading, Correction, and Approval of Previous Minutes

The February 12, 2019 DUR Board Meeting minutes were approved.

DUR Committee Report

G. Master presented a summary of the RetroDUR intervention directed at the prescribers of members with pharmacy claims for antidiabetic medications who appeared to be nonadherent to medications.

G. Master presented a summary of the RetroDUR intervention directed at prescribers of members with pharmacy claims for insulin, but no pharmacy claims for blood glucose test strips.

G. Master presented the re-review results from the intervention directed at prescribers of patients with diabetes who were not taking a statin, angiotensin converting enzyme (ACE) inhibitor, or angiotensinogen receptor blocker (ARB). Upon re-review, 27% of patients had the recommended medication added.

Dr. Mostafavifar recommended a prescriber mailing entailing the new lipid guidelines.

G. Master provided an update to the Board on the Coordinated Services Program (CSP) membership. Currently, 226 Fee-for-Service members are enrolled. July 2019 will be the end of the 24-month enrollment period for the first members.

Health Plan Policy

M. Barger announced that The Ohio Department of Medicaid (ODM) has decided to move forward with the Single Preferred Drug List (PDL) initiative. Implementation is anticipated to be no later than January 1st of 2020. Additional information will be communicated during future Pharmacy DUR Board and P&T Committee meetings.
ODM has put in place a new process for scheduling drug manufacturer meetings called Pharmacy Third Party Resource Day. Moving forward, manufacturers should complete and return a short form (which can be requested by contacting their shared Medicaid Pharmacy mailbox) and they will assign a timeslot.

The Centers for Medicare and Medicaid Services (CMS) Annual Drug Utilization Review (DUR) Report is due July 1st. This is the first year that Managed Care Plan DUR program information will be included in the report submission.

New Business

G. Master introduced background on provider submitted DUR code values and explained that states are asked in the CMS DUR Annual Report if they review pharmacy provider DUR alert override activity. Previously, the DUR Committee reviewed and recommended removing 65 severity 3 DUR drug-drug interactions from the point of sale. A. Mostafavifar and S. Rexrode-Brewer advocated for removing these interactions to help alleviate DUR fatigue. Dr. Mostafavifar suggested drug-drug interactions be sent to prescribers depending on their specialty and Dr. Farrell indicated he would like to see severity 1 and 2 interactions. The DUR Board was in favor of limiting drug-drug interaction pharmacist fatigue but asked for additional follow up. M. Barger stated that the DUR Committee will meet again to discuss this issue further and the consensus will then be brought to the Board.

B. Link introduced the concept of extending the package side edit to include medications that are recommended to be dispensed in the original packaging. B. Link then reviewed Pradaxa and oxcarbazepine packaging rules as well as finasteride exposure to females. The DUR Board recommended pursuing this edit.

RetroDUR prescriber letter templates and surveys were reviewed.

Announcements

Per A. Mostafavifar, ODM Director Maureen Corcoran will be speaking at The Ohio State University on October 11th, at the Fawcett Center.

The dates for the next DUR Board meetings were set as follows:

- September 17, 2019
- November 12, 2019

Adjournment

Dr. Mostafavifar adjourned the meeting at 1:02 P.M.